PFE: FDA Approves IBRANCE
Pfizer's IBRANCE regimen is approved by the FDA for HR+, HER2+ metastatic breast cancer frontline maintenance
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.